If you’re like me and have also pulled almost everything out of your fridge to find your go-to salad dressing or that one ...

Imugene has dosed the first Australian subject in a Phase Ib trial of its allogeneic CAR T-cell therapy, azer-cel (azercabtagene zapreleucel).

Imugene Ltd (ASX:IMU, OTC:IUGNF) has launched a Phase 1b clinical trial at the Royal Prince Alfred Hospital in Sydney, dosing the first Australian patient with its allogeneic CAR T-cell therapy ...

Imugene Limited (AU:IMU) has released an update.Don't Miss Our New Year's Offers:Discover the latest stocks recommended by top Wall Street ...

In a new book, a science journalist recounts the story of a lifesaving treatment for infection that scientists broadly ...

NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and ...

The director of solid tumor therapy at Stanford Medicine describes how cellular therapies are transforming cancer care.

This is the time of year when I am developing the schedule of adult programs for January through May. I have some exciting things in the works! On Jan. 12 at 2 p.m., local resident Jacquelyn Moser ...

CRISPR Therapeutics (NASDAQ: CRSP) isn't a stock that's wanting for reasons to invest. Per the company's presentation at the American Society of Hematology's (ASH) annual meeting on Dec. 9, the Food ...

Tyler Perry reminds us that starting therapy is never too late. The director was recently a guest on The View and revealed that he began therapy for the first time at 54. Perry said a question ...

The ability to suppress NK-mediated rejection is a key advancement in enabling off-the-shelf CAR-T therapy, supporting the potential to overcome scalability, logistics and cost challenges ...